CSF2 and pancreatic neoplasm: Thus, this trial incorporated four distinct strategies to increase the potency of anti-tumor immunity in pancreatic cancer patients – targeting multiple tumor antigens, expression of several T-cell costimulatory molecules, delivery using a heterologous prime-boost poxvirus system and inclusion of GM-CSF as a local adjuvant.